# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Fresenius Medical Care invests EUR 312 million and successfully closes a share purchase agreement with all non-physician invest...
UBS analyst Graham Doyle downgrades Fresenius Medical Care (NYSE:FMS) from Neutral to Sell.
FDA approves Amphastar's iron sucrose injection for CKD-associated anemia, with potential for $80-100 million sales and a 2...
Outlook 2025 confirmedFresenius Medical Care confirms its outlook for fiscal 2025 and expects revenue growth to be positive to ...